Aeglea BioTherapeutics
a conservative spy product profile was tested against and morphic as agent | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
September 2023
Slide
28 of 56
Similar slides by Aeglea BioTherapeutics
See diffirences between slides (animation)
Investor Presentation
July 2023
the base case spy profile was conservatively compared to and morphic | Aeglea BioTherapeutics
Related slides by other companies
Ocuphire Pharma
Results
October 2022
product candidate profile for multiple retinal indications | Ocuphire Pharma
ATAI
Investor Presentation
October 2022
at home unsupervised administration will be based upon a demonstration of an effective dose with good safety and tolerability phase a results anticipated around end of year safety tolerability efficacy of single dose administration with in phase study of subcutaneous formulation relative initiating in is being developed as potential rapid acting treatment for administered setting at home ras | ATAI
Larimar Therapeutics
Results
November 2022
safety and of single and day multiple dose administration of a replacement therapy for ataxia nancy do galas | Larimar Therapeutics
3M
Mergers and Acquisitions
December 2021
food safety product offerings | 3M
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
July 2023
Mergers and Acquisitions
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io